Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment of NKTCL

NCT04509466 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

41

Enrollment

INDUSTRY

Sponsor class

Stopped The sponsor has adjusted its R\&D strategy.

Conditions

Extranodal NK/T-cell Lymphoma, Nasal Type

Interventions

DRUG: Part 1: Liposomal mitoxantrone hydrochloride and Pegaspargase
DRUG: Part 2 (treatment-naïve patients): Liposomal mitoxantrone hydrochloride and Pegaspargase
DRUG: Part 2 (relapsed or refractory patients): Liposomal mitoxantrone hydrochloride and Pegaspargase

Sponsor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.